The previous results showed that the mRNA expression of FLT3 was decreased in 64% of patients with HCC because of the loss of gene copy number; however, patients with high FLT3 expression benefit from sorafenib, which improves prognosis [34]. Here, FLT3 is linked to hepatocellular carcinoma.